相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
Ondrej Kalous et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors
Pasi A. Jaenne et al.
CLINICAL CANCER RESEARCH (2011)
Lapatinib, a Dual EGFR and HER2 Kinase Inhibitor, Selectively Inhibits HER2-Amplified Human Gastric Cancer Cells and is Synergistic with Trastuzumab In vitro and In vivo
Zev A. Wainberg et al.
CLINICAL CANCER RESEARCH (2010)
Identification of Common Predictive Markers of In vitro Response to the Mek Inhibitor Selumetinib (AZD6244; ARRY-142886) in Human Breast Cancer and Non-Small Cell Lung Cancer Cell Lines
Edward B. Garon et al.
MOLECULAR CANCER THERAPEUTICS (2010)
KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma
John P. Morris et al.
NATURE REVIEWS CANCER (2010)
A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer
J. Randolph Hecht et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
Richard S. Finn et al.
BREAST CANCER RESEARCH (2009)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor
Andrea J. Gonzales et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Recent advances in head and neck cancer
Robert I. Haddad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Platinum-based chemotherapy plus cetuximab in head and neck cancer
Jan B. Vermorken et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib
Jeffrey A. Engelman et al.
CANCER RESEARCH (2007)
EGF receptor ubiquitination is not necessary for its internalization
Fangtian Huang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial
Ulrich Gatzemeier et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
Charles E. Geyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
PIK3CA mutations in head and neck squamous cell carcinoma
WL Qiu et al.
CLINICAL CANCER RESEARCH (2006)
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
JA Bonner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells
GE Konecny et al.
CANCER RESEARCH (2006)
Epidermal growth factor receptor (EGFR) signaling in cancer
N Normanno et al.
GENE (2006)
ERBB receptors and cancer: The complexity of targeted inhibitors
NE Hynes et al.
NATURE REVIEWS CANCER (2005)
Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck
JW Lee et al.
CLINICAL CANCER RESEARCH (2005)
Structural basis for inhibition of the epidermal growth factor receptor by cetuximab
SQ Li et al.
CANCER CELL (2005)
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
S Kobayashi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Opinion - Profiling early head and neck cancer
KD Hunter et al.
NATURE REVIEWS CANCER (2005)
Prognostic significance of EGF receptor expression in early glottic cancer
A Demiral et al.
AURIS NASUS LARYNX (2004)
EGFRvIII-mediated radioresistance through a strong cytoprotective response
G Lammering et al.
ONCOGENE (2003)
Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer
J Mendelsohn et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer
M Fukuoka et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Issues and progress with protein kinase inhibitors for cancer treatment
J Dancey et al.
NATURE REVIEWS DRUG DISCOVERY (2003)
Detection of mycoplasma in leukemia-lymphoma cell lines using polymerase chain reaction
CC Uphoff et al.
LEUKEMIA (2002)
Monoclonal antibodies to target epidermal growth factor receptor-positive tumors - A new paradigm for cancer therapy
RS Herbst et al.
CANCER (2002)
分享论文
